ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party

Ronald F. van Vollenhoven1, Marta Mosca2, George Bertsias3, Annegret Kuhn4, Kirsten Lerstrøm5, Josef S. Smolen6, David A. Isenberg7, Matthias Schneider8 and the T2T/SLE Working Party9, 1Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, 2I, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, 3Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, 4University of Münster, Münster, Germany, 5Lupus Europe, Farum, Denmark, 6Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 7Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 8Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, 9the Karolinska Institute, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects II: Central Nervous System Manifestations, Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and pursuing these systematically has led to improved care for patients with these diseases and useful guidance for health care providers and administrators. Thus, an initiative to evaluate possible therapeutic targets and develop treat-to-target guidance was believed to be of benefit in SLE as well. An expert panel was convened for this purpose.

Methods: Thirty-four specialists in rheumatology, nephrology, dermatology and/or clinical immunology and a patient representative contributed to this initiative. The majority convened on three occasions. Twelve topics of critical importance for this endeavor were identified and a systematic literature review (SLR) was performed on these topics. The results of the SLR were condensed and reformulated as recommendations, discussed, modified, and voted upon. The finalized bullet points were analyzed for degree of agreement among the panel (strength of recommendation, SoR). The Oxford Center level of evidence (LoE, corresponding to the research questions, not shown) and grade of recommendation (GoR) were determined for each recommendation.

Results: The twelve systematic literature searches and their summaries led to eleven recommendations (Table). LoE and GoR of the recommendations were variable but agreement was >0.9 in each case.  An extensive research agenda was identified, and four overarching principles were also agreed upon.

Table:

Conclusion: Treat-to-target-in-SLE (T2T/SLE) recommendations were developed by a large panel of multi-specialty experts and a patient representative. Although LoE and GoR were variable, agreement was excellent. Prominent features of these recommendations are targeting remission, preventing damage, and improving quality of life. It is anticipated that “treating-to-target” can and will be applicable to the care of patients with SLE.


Disclosure:

R. F. van Vollenhoven,

AbbVie, BMS, GSK, Merck, Pfizer, Roche, UCB,

2,

AbbVie, AstraZeneca, Biotest, BMS, GSK, Lilly, Merck, Pfizer, Roche, UCB, Vertex,

5;

M. Mosca,
None;

G. Bertsias,
None;

A. Kuhn,
None;

K. Lerstrøm,
None;

J. S. Smolen,

AbbVie Inc., Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo-Nordisk, Roche, Sandoz, and UCB,

2,

AbbVie Inc., Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo-Nordisk, Roche, Sandoz, and UCB,

5;

D. A. Isenberg,

I have consulted for a number of companiews including GSK, Roche, UCB and teva. I arrange for the payments offered to go a local arthritis charity .,

5;

M. Schneider,
None;

T. T. Working Party,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treat-to-target-in-systemic-lupus-erythematosus-report-from-the-t2tsle-working-party/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology